Takotsubo cardiomyopathy concurrent with hyperthyroidism following COVID-19—a case report and literature review - Report - MDSpire

Takotsubo cardiomyopathy concurrent with hyperthyroidism following COVID-19—a case report and literature review

  • By

  • Liya Lin

  • Shanshan Liu

  • Yi Fang

  • Qijing Zhou

  • Minyue Jia

  • Hanxiao Yu

  • Kai Cheok

  • Xuehua Zhang

  • Lingxia Ye

  • Xiaoxiao Song

  • July 8, 2026

  • 0 min

Share

Clinical Report: Takotsubo Cardiomyopathy Associated with Hyperthyroidism After COVID-19

Overview

This case report details a 21-year-old male who developed Takotsubo cardiomyopathy following SARS-CoV-2 infection, exacerbated by hyperthyroidism.

Background

Takotsubo cardiomyopathy (TTS) is characterized by transient left ventricular dysfunction often mimicking acute coronary syndrome. The condition has gained recognition due to its association with various stressors, including viral infections and endocrine disorders.

Data Highlights

No numerical or trial data provided in the article.

Key Findings

  • A 21-year-old male developed TTS two weeks post-SARS-CoV-2 infection.
  • Clinical features included sinus tachycardia and anterior ST-segment elevation on ECG.
  • Thyrotoxicosis was confirmed through biochemical and imaging studies.
  • Cardiac magnetic resonance imaging showed subendocardial hypoperfusion and abnormal myocardial motion.
  • Treatment with methimazole and beta-blockers resulted in resolution of cardiac dysfunction.

Clinical Implications

Thyroid evaluation may be warranted in COVID-19 patients presenting with cardiac symptoms.

Conclusion

This case highlights the interactions between COVID-19, hyperthyroidism, and Takotsubo cardiomyopathy.

Related Resources & Content

  1. Clinical Research in Cardiology, 2020 -- Psychological Impact of SARS-CoV-2 Infection Leading to Takotsubo Cardiomyopathy
  2. Frontiers in Endocrinology, 2026 -- Permanent hypoparathyroidism following SARS-CoV-2 infection: a case report with two-year follow-up and literature review
  3. Frontiers in Cardiovascular Medicine, 2026 -- Long-term cardiovascular impact of COVID-19 among hospitalised and non-hospitalised populations: a narrative synthesis review
  4. The Journal of Clinical Endocrinology & Metabolism -- Management Strategies for Patients Experiencing Thyroid Storm
  5. 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes, JACC
  6. Takotsubo Cardiomyopathy - StatPearls - NCBI Bookshelf
  7. Temporal Trends in Takotsubo Syndrome: Results From the International Takotsubo Registry, JACC
  8. Beta-Blocker Therapy in Patients With Takotsubo Syndrome Associated With Lower Mortality - American College of Cardiology
  9. 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines | JACC
  10. Efficacy of beta-blocker therapy in Takotsubo cardiomyopathy: A systematic review and meta-analysis - ScienceDirect
  11. Takotsubo syndrome: pathophysiological insights and innovations in patient care | Nature Reviews Cardiology
  12. Takotsubo Syndrome in Patients With COVID-19: A Systematic Review - PMC
  13. Subacute thyroiditis as a post-COVID-19 complication: a systematic review | BMC Infectious Diseases | Springer Nature Link
  14. The association between Takotsubo cardiomyopathy and thyrotoxicosis: A systematic review - PubMed

Original Source(s)

Takotsubo cardiomyopathy concurrent with hyperthyroidism following COVID-19—a case report and literature review

  • by Liya Lin, Shanshan Liu, Yi Fang, Qijing Zhou, Minyue Jia, Hanxiao Yu, Kai Cheok, Xuehua Zhang, Lingxia Ye, Xiaoxiao Song

  • July 8, 2026

Related Content

Research hotspots and trend of the heart-brain axis by MRI: a bibliometric analysis

Chronological age was not independently associated with ultra-early safety or arrhythmic outcomes after contemporary atrial fibrillation ablation: a real-world single-center study

Biochanin A attenuates doxorubicin-induced cardiotoxicity in rats with associated modulation of PI3K/Akt/mTOR and p38 MAPK signaling